Gynecologic and Hormonal Effects of Raloxifene in Premenopausal Women

Fertil Steril. 2007 Dec;88(6):1637-44. doi: 10.1016/j.fertnstert.2007.01.095. Epub 2007 Jul 26.

Abstract

Objective: To assess the effects of raloxifene on the ovaries, uterus, and serum hormone levels in premenopausal women.

Design: Prospective study comparing pretreatment findings with findings for those on treatment.

Setting: Government research hospital.

Patient(s): Thirty women 35 to 47 years of age who were at high risk of breast cancer and had regular, ovulatory menstrual cycles.

Intervention(s): Raloxifene (60 mg) and calcium (1,200 mg) daily for 2 years.

Main outcome measure(s): Sonographic evidence of ovarian stimulation (>or=2 corpora lutea, or follicular cysts of >2 cm, or single follicular cyst of >3 cm). Changes in endometrial thickness, fibroid size, hormone levels, and menstrual-cycle length.

Result(s): Fifteen subjects developed some cycles with asymptomatic ovarian stimulation, and 9 developed benign endometrial polyps, compared with 2 subjects and 1 subject pretreatment, respectively. Uterine fibroid size was unchanged during raloxifene use in 16 subjects with fibroids. On treatment, E(2) levels increased significantly only during the follicular phase, with peak E(2) levels significantly higher in cycles showing ovarian stimulation compared with those without. Sex hormone-binding globulin increased, but levels of LH, FSH, P, DHEAS, and T did not. Endometrial thickness and cycle length were unchanged.

Conclusion(s): Premenopausal subjects receiving raloxifene showed sonographic and hormonal evidence of ovarian stimulation. Endometrial thickness, cycle length, and fibroid size were unchanged. Benign asymptomatic endometrial polyps developed in some.

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Breast Neoplasms / etiology
  • Breast Neoplasms / prevention & control*
  • Calcium Carbonate / administration & dosage
  • Carcinoma / etiology
  • Carcinoma / prevention & control*
  • Dehydroepiandrosterone Sulfate / blood
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Genitalia, Female / diagnostic imaging
  • Genitalia, Female / drug effects*
  • Gonadal Steroid Hormones / blood*
  • Humans
  • Menstrual Cycle / blood
  • Middle Aged
  • Polyps / chemically induced
  • Polyps / diagnostic imaging
  • Premenopause / drug effects*
  • Raloxifene Hydrochloride / administration & dosage
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / therapeutic use*
  • Risk Factors
  • Selective Estrogen Receptor Modulators / administration & dosage
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Ultrasonography
  • Uterine Diseases / chemically induced
  • Uterine Diseases / diagnostic imaging

Substances

  • Gonadal Steroid Hormones
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Dehydroepiandrosterone Sulfate
  • Calcium Carbonate